Twist Bioscience (NASDAQ:TWST) Sets New 52-Week High After Analyst Upgrade

Twist Bioscience Corporation (NASDAQ:TWST)’s share price hit a new 52-week high on Tuesday after Robert W. Baird raised their price target on the stock from $113.00 to $115.00. Robert W. Baird currently has an outperform rating on the stock. Twist Bioscience traded as high as $106.58 and last traded at $101.4690, with a volume of 87911 shares trading hands. The stock had previously closed at $101.06.

Several other research firms have also commented on TWST. Barclays increased their target price on shares of Twist Bioscience from $65.00 to $95.00 and gave the company an “overweight” rating in a research note on Wednesday, June 24th. Canaccord Genuity Group lifted their price target on shares of Twist Bioscience from $90.00 to $120.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. UBS Group set a $89.00 price target on Twist Bioscience in a report on Monday, June 15th. Evercore downgraded Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price objective for the company. in a research report on Monday, July 6th. Finally, Piper Sandler began coverage on Twist Bioscience in a research note on Thursday, June 11th. They set an “overweight” rating and a $85.00 price objective for the company. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $95.30.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, insider Dennis Cho sold 14,205 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $89.75, for a total transaction of $1,274,898.75. Following the completion of the sale, the insider directly owned 105,141 shares in the company, valued at approximately $9,436,404.75. This trade represents a 11.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jan Johannessen sold 12,000 shares of the company’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $56.12, for a total value of $673,440.00. Following the completion of the transaction, the director owned 17,754 shares in the company, valued at $996,354.48. This represents a 40.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 50,211 shares of company stock worth $4,199,331. 3.08% of the stock is currently owned by company insiders.

More Twist Bioscience News

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Raised fiscal 2026 outlook: Twist increased full-year revenue guidance to $456 million-$457 million from $442 million-$447 million, above the roughly $446.5 million analyst consensus. Fourth-quarter revenue guidance of $123 million-$124 million also exceeds the $117.5 million consensus, signaling sustained demand and improving execution. Twist Bioscience fiscal 2026 outlook
• Positive Sentiment: Revenue beat and continued growth: Fiscal third-quarter revenue rose 23.2% year over year to $118.38 million, exceeding estimates of $114.55 million. Investors may be placing greater weight on accelerating revenue and management’s target of reaching adjusted EBITDA breakeven in the fourth quarter of fiscal 2026. Twist Bioscience third-quarter results
• Positive Sentiment: Baird raised its price target: Robert W. Baird lifted its target from $113 to $115 and maintained an “outperform” rating. The new target implies approximately 13.8% upside from the referenced $101.06 price, reinforcing the bullish analyst view. Benzinga analyst action
• Neutral Sentiment: Mixed institutional signals: Recent filings show 138 institutional investors added TWST shares while 111 reduced positions. This indicates continued institutional interest but also notable portfolio rebalancing.
• Negative Sentiment: Quarterly loss exceeded expectations: Twist reported an adjusted loss of $0.56 per share, worse than the expected $0.51 loss and the $0.47 loss recorded a year earlier. The disappointing EPS result initially pressured the shares despite the revenue beat. Twist Bioscience fiscal third-quarter loss
• Negative Sentiment: Insider selling: Reported insider activity over the past six months shows 76 sales and no purchases, including sales by senior executives. While these transactions may reflect compensation or diversification, the lack of insider buying could weigh on sentiment.

Institutional Trading of Twist Bioscience

Hedge funds and other institutional investors have recently modified their holdings of the company. GAMMA Investing LLC grew its holdings in Twist Bioscience by 24.4% in the 2nd quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock valued at $97,000 after buying an additional 185 shares during the last quarter. Stifel Financial Corp increased its position in Twist Bioscience by 3.6% in the 4th quarter. Stifel Financial Corp now owns 7,769 shares of the company’s stock worth $246,000 after buying an additional 271 shares during the period. D.A. Davidson & CO. lifted its holdings in shares of Twist Bioscience by 1.2% during the fourth quarter. D.A. Davidson & CO. now owns 25,237 shares of the company’s stock worth $801,000 after buying an additional 305 shares during the last quarter. CWM LLC lifted its holdings in shares of Twist Bioscience by 9.4% during the fourth quarter. CWM LLC now owns 4,738 shares of the company’s stock worth $150,000 after buying an additional 407 shares during the last quarter. Finally, California State Teachers Retirement System boosted its position in shares of Twist Bioscience by 0.8% in the second quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock valued at $1,994,000 after acquiring an additional 442 shares during the period.

Twist Bioscience Stock Down 0.3%

The firm has a 50-day moving average price of $85.80 and a two-hundred day moving average price of $62.56. The company has a market capitalization of $6.27 billion, a P/E ratio of -75.97 and a beta of 2.14. The company has a quick ratio of 2.42, a current ratio of 2.70 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The company had revenue of $118.38 million for the quarter, compared to the consensus estimate of $114.55 million. Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The company’s revenue was up 23.2% compared to the same quarter last year. During the same period last year, the firm posted $0.33 EPS. Equities research analysts anticipate that Twist Bioscience Corporation will post -2.02 EPS for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.